DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Quetiapine fumarate (Drug); conventional treatment for schizophrenia (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Martin Brecher, MD, Study Director, Affiliation: AstraZeneca

Summary

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

Clinical Details

Official title: An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia.

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Primary outcome: Social outcome measured by Strauss-Carpenter scale

Secondary outcome:

Change in PANSS total score

Change in PANSS positive, negative and general psychopathology symptom subscales

Change in cognition as measured by a Cognitive Battery of Tests

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed informed consent

- Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at

least 2 years.

- Clinically stable and in an outpatient setting before entering the study (visit 1).

Exclusion Criteria:

- Use of clozapine and quetiapine within two months prior to visit 1.

- If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III

test at visit 1.

Locations and Contacts

Research Site, ESKILSTUNA, Sweden

Research Site, GÖTEBORG, Sweden

Research Site, HUDDINGE, Sweden

Research Site, JÖNKÖPING, Sweden

Research Site, LIMHAMN, Sweden

Research Site, LUND, Sweden

Research Site, MALMÖ, Sweden

Research Site, NORSBORG, Sweden

Research Site, STOCKHOLM, Sweden

Research Site, Umeå, Sweden

Research Site, Vasteras, Sweden

Research Site, Lidingö, Sweden

Research Site, Nyköping, Sweden

Research Site, Trollhättan, Sweden

Research Site, Hisingsbacka, Sweden

Additional Information

Starting date: September 2005
Ending date: December 2007
Last updated: January 25, 2008

Page last updated: March 21, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009